When these two investigations were planned, pembrolizumab was approved as monotherapy for previously untreated patients with NSCLC with high PD‐L1 expression and previously treated patients with NSCLC with TPS ≥1%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.